Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Thomas Wex
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Thomas Wex wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. 2012

Link, Alexander / Becker, Verena / Goel, Ajay / Wex, Thomas / Malfertheiner, Peter. ·Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany. alinkmail@gmail.com ·PLoS One · Pubmed #22905187.

ABSTRACT: INTRODUCTION: Pancreatic cancer (PCA) is an aggressive tumor that associates with high mortality rates. Majority of PCA patients are diagnosed usually at late tumor stages when the therapeutic options are limited. MicroRNAs (miRNA) are involved in tumor development and are commonly dysregulated in PCA. As a proof-of-principle study, we aimed to evaluate the potential of fecal miRNAs as biomarkers for pancreatic cancer. MATERIALS AND METHODS: Total RNA was extracted from feces using Qiagen's miRNA Mini Kit. For miRNA expression analyses we selected a subset of 7 miRNAs that are frequently dysregulated in PCA (miR-21, -143, -155, -196a, -210, -216a, -375). Subsequently, expression levels of these miRNAs were determined in fecal samples from controls (n = 15), chronic pancreatitis (n = 15) and PCA patients (n = 15) using quantitative TaqMan-PCR assays. RESULTS: All selected miRNAs were detectable in fecal samples with high reproducibility. Four of seven miRNAs (miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05). Analysis of fecal miRNA expression in controls and patients with chronic pancreatitis and PCA revealed that the expression of miR-216a, -196a, -143 und -155 were highest in controls and lowest in PCA. The expression of the remaining three miRNAs (miR-21, -210 and -375) remained unchanged among controls and the patients with either chronic pancreatitis or PCA. CONCLUSION: Our data provide novel evidence for the differential expression of miRNAs in feces of patients with PCA. If successfully validated in large-scale prospective studies, the fecal miRNA biomarkers may offer novel tools for PCA screening research.

2 Article [Helicobacter pylori infection in pancreatic cancer]. 2012

Gawin, Alicja / Wex, Thomas / Ławniczak, Małgorzata / Malfertheiner, Peter / Starzyńska, Teresa. ·Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland. k.gastro@sci.pam.szczecin.pl ·Pol Merkur Lekarski · Pubmed #22590913.

ABSTRACT: MATERIAL AND METHODS: 139 patients with pancreatic cancer and 177 controls were included in the study. Seropositivity for H. pylori, including CagA protein were assessed by the enzyme-linked immunosorbent assay and Western blot, respectively. The frequency of H. pylori in pancreatic cancer patients and controls were compared adjusted for age, sex, cigarette smoking and a family history of cancer in the logistic regresion model. RESULTS: No significant differences between pancreatic cancer patients and controls were seen according to H. pylori seropositivity (87.1 vs 82.5%; OR = 1.27; CI95%: 0.64-2.61; p = 0.514) and CagA seropositivity (83.5 vs 84.9%; OR = 0.90; CI95%: 0.46-1.73; p = 0.744). CONCLUSIONS: The study didn't support previous observations of H. pylori infection as a plausible pathogenic risk factor for pancreatic cancer development. The high prevalence of infection in the control group may explain why the earlier reports of a positive association between H. pylori infection and pancreatic cancer could not be confirmed in the study.